Gallbladder Disease: Increased risk of gallstones, especially in individuals with existing gallbladder problems
GLP-1 (Glucagon-Like Peptide-1) as distributed by Peptides Lab UK is not intended for, and must not be used for, human consumption, medical treatment, self-administration, veterinary applications, or any use outside of a controlled laboratory environment
Semaglutide (marketed under the brand name Wegovy) and liraglutide (Saxenda) did lead to weight loss, but it was significantly less at 15% and 8%, respectively
These patches are often promoted as: A cheaper alternative to injections
Specific medication guides for early dosing Each GLP-1 medication has its own characteristics that affect early dosing decisions
The litigation focuses on severe, documented injuries that required medical treatment, hospitalization, or resulted in permanent harm